ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 204 filers reported holding ARCUS BIOSCIENCES INC in Q4 2022. The put-call ratio across all filers is 2.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $379 | -0.5% | 21,138 | +1.2% | 0.03% | -15.8% |
| Q1 2023 | $381 | -38.8% | 20,886 | -30.6% | 0.04% | -50.6% |
| Q4 2022 | $623 | -99.8% | 30,108 | +204.5% | 0.08% | +102.6% |
| Q2 2022 | $251,000 | -49.7% | 9,888 | -37.5% | 0.04% | -43.3% |
| Q1 2022 | $499,000 | +98.8% | 15,809 | +154.6% | 0.07% | +109.4% |
| Q4 2021 | $251,000 | -53.1% | 6,210 | -80.1% | 0.03% | -64.0% |
| Q3 2020 | $535,000 | +129.6% | 31,217 | +231.5% | 0.09% | -31.5% |
| Q2 2020 | $233,000 | -49.6% | 9,417 | -71.7% | 0.13% | +12.1% |
| Q1 2020 | $462,000 | -35.2% | 33,319 | -52.8% | 0.12% | +39.8% |
| Q4 2019 | $713,000 | +99.2% | 70,619 | +79.4% | 0.08% | +72.9% |
| Q3 2019 | $358,000 | +177.5% | 39,354 | +142.3% | 0.05% | +242.9% |
| Q2 2019 | $129,000 | -25.4% | 16,243 | +17.3% | 0.01% | -22.2% |
| Q1 2019 | $173,000 | – | 13,851 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |